Alpha Tau Medical Ltd.
Business
Alpha Tau Medical Ltd. is a clinical-stage oncology company developing Alpha DaRT®, a proprietary localized alpha-particle radiation therapy for solid tumors. The technology utilizes Radium-224–embedded radioactive sources to deliver targeted alpha radiation directly into tumors, with applications across multiple cancer types including squamous cell carcinoma, pancreatic cancer, glioblastoma, and others. The company is conducting 11 clinical trials globally, with regulatory approvals including FDA Breakthrough Device Designations and marketing authorization in Israel and Japan, while pursuing U.S. FDA approval and commercialization in multiple geographies.
Summary from 20-F filed 2026-03-09
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-42.63M |
| Total assets | $105.65M |
| Total liabilities | $28.55M |
| Stockholders' equity | $77.10M |
| Operating cash flow | $-26.68M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Alpha Tau Medical Ltd.'s CIK number?
Alpha Tau Medical Ltd.'s SEC CIK number is 0001871321 (1871321). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Alpha Tau Medical Ltd.'s SEC filings?
All of Alpha Tau Medical Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.